CD4 and CD4+/CD56+ hematodermic neoplasm: In 2022, the WHO specified that to make the diagnosis of BPDCN, the expression of CD123, CD4, CD56, and another pDC marker (CD303, 304, TCL1, or TCF4) is required [8,23].